Soleno Therapeutics Inc (SLNO.OQ)
25 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|49||2017||President, Chief Executive Officer, Interim Principal Financial and Accounting Officer, Director|
|67||2017||Interim Chief Financial Officer|
|55||2013||Vice President - Research and Development|
|2014||Chairman of the Board|
- BRIEF-Soleno Therapeutics Reports Q4 Loss Per Share $0.43
- BRIEF-Soleno Therapeutics Announces Successful End-Of-Phase II Meeting With FDA For DCCR In Prader-Willi Syndrome
- BRIEF-Soleno Therapeutics Files For Resale Of Up To 14.2 Mln Shares
- BRIEF-Jack W. Schuler Living Trust Reports 13.4 Pct Stake In Soleno Therapeutics As Of December 15
- BRIEF-Soleno Therapeutics Says Board Resolved To Decrease Size Of Board From Ten To Seven